Sphera Funds Management LTD. lowered its stake in shares of GlaxoSmithKline plc (NYSE:GSK) by 64.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 310,000 shares of the pharmaceutical company’s stock after selling 555,000 shares during the period. GlaxoSmithKline accounts for about 1.3% of Sphera Funds Management LTD.’s investment portfolio, making the stock its 19th largest position. Sphera Funds Management LTD.’s holdings in GlaxoSmithKline were worth $11,845,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently added to or reduced their stakes in GSK. Russell Investments Group Ltd. acquired a new position in shares of GlaxoSmithKline during the third quarter valued at about $436,000. Commonwealth Equity Services LLC boosted its position in GlaxoSmithKline by 1.8% in the third quarter. Commonwealth Equity Services LLC now owns 420,893 shares of the pharmaceutical company’s stock valued at $16,907,000 after buying an additional 7,580 shares during the last quarter. Systematic Financial Management LP purchased a new stake in GlaxoSmithKline in the third quarter valued at approximately $823,000. LSV Asset Management boosted its position in GlaxoSmithKline by 3.3% in the third quarter. LSV Asset Management now owns 480,650 shares of the pharmaceutical company’s stock valued at $19,307,000 after buying an additional 15,350 shares during the last quarter. Finally, Advisor Partners LLC boosted its position in GlaxoSmithKline by 26.0% in the third quarter. Advisor Partners LLC now owns 16,765 shares of the pharmaceutical company’s stock valued at $673,000 after buying an additional 3,462 shares during the last quarter. Hedge funds and other institutional investors own 11.07% of the company’s stock.

GlaxoSmithKline stock traded up $0.12 during mid-day trading on Thursday, hitting $40.47. The company had a trading volume of 287,967 shares, compared to its average volume of 2,289,474. The company has a current ratio of 0.75, a quick ratio of 0.51 and a debt-to-equity ratio of 5.52. GlaxoSmithKline plc has a 12-month low of $36.13 and a 12-month high of $42.36. The firm has a market cap of $100.41 billion, a PE ratio of 12.81, a P/E/G ratio of 2.01 and a beta of 0.76.

GlaxoSmithKline (NYSE:GSK) last released its quarterly earnings data on Wednesday, February 6th. The pharmaceutical company reported $0.79 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.70 by $0.09. GlaxoSmithKline had a return on equity of 160.39% and a net margin of 11.45%. The business had revenue of $10.55 billion for the quarter, compared to analyst estimates of $9.85 billion. On average, equities research analysts forecast that GlaxoSmithKline plc will post 2.88 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 11th. Shareholders of record on Friday, February 22nd will be given a $0.597 dividend. This represents a $2.39 annualized dividend and a yield of 5.90%. The ex-dividend date of this dividend is Thursday, February 21st. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.49. GlaxoSmithKline’s dividend payout ratio is currently 74.68%.

A number of equities research analysts recently commented on GSK shares. Jefferies Financial Group reiterated a “buy” rating and issued a $45.00 target price on shares of GlaxoSmithKline in a research report on Tuesday, December 11th. Morgan Stanley started coverage on GlaxoSmithKline in a research report on Friday, December 14th. They issued an “underweight” rating on the stock. Exane BNP Paribas lowered GlaxoSmithKline from an “outperform” rating to a “neutral” rating in a research report on Monday, January 14th. BNP Paribas lowered GlaxoSmithKline from an “outperform” rating to a “neutral” rating in a research report on Monday, January 14th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline in a research report on Monday, December 3rd. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $41.99.

TRADEMARK VIOLATION WARNING: This article was published by Daily Political and is owned by of Daily Political. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://www.dailypolitical.com/2019/03/14/glaxosmithkline-plc-gsk-stake-lessened-by-sphera-funds-management-ltd.html.

GlaxoSmithKline Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

See Also: Balanced Fund

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.